Publications

  1. Mernaugh, RL, Shearer, MH, Bright, RK, Lanford, RE and Kennedy, RC. Idiotype network components are involved in the murine immune response to simian virus 40 large tumor antigen. Cancer Immunol. Immunother. 35:113-118, 1992.
  2. Shearer, MH, Bright, RK, Lanford, RE and Kennedy, RC. Immunization of mice with baculovirus-derived recombinant SV40 large tumor antigen induces protective tumor immunity to a lethal challenge with SV40-transformed cells. Clin. Exp. Immunol. 91:266- 271, 1993.
  3. Bright, RK, Shearer, MH, and Kennedy, RC. Comparison of the murine humoral immune response to recombinant SV40 large tumor antigen: Epitope specificity and idiotype expression.  Cancer Immunol. Immunother. 37:31-39, 1993.
  4. Shearer, MH, Bright, RK, and Kennedy, RC. Comparison of humoral immune responses and tumor immunity in mice immunized with recombinant SV40 large tumor antigen and a monoclonal anti-idiotype.  Cancer Res. 53:5734-5739, 1993.
  5. Bright, RK, Shearer, MH and Kennedy, RC. Examination of the fine specificity of the murine immune response to SV40 T-ag utilizing synthetic peptides that define selected epitopes. Clin. Exp. Immunol.96:491-499,1994.
  6. Sadziene, A, Jonsson, M, Bergström, S, Bright, RK, Kennedy, RC and Barbour, AG. A bacterial antibody to Borrelia burgdorferi is directed against a variable region of OspB protein. Infect. Immun. 62:2037-2045, 1994.
  7. Bright, RK, Shearer, MH and Kennedy, RC. SV40 large tumor antigen associated synthetic peptides define native antigenic determinants and induce protective tumor immunity in mice. Mol. Immunol. 31:1077-1087, 1994.
  8. Bright, RK, Shearer, MH and Kennedy, RC. Immunization of BALB/c mice with recombinant SV40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity (ADCC) against SV40 transformed cells: an antibody based mechanism for tumor immunity. J. Immunol. 153:2064-2071, 1994.
  9. Shearer, MH, Bright, RK and Kennedy, RC. Molecular characterization of immunoglobulin variable regions from murine monoclonal antibodies specific for simian virus 40 large tumor antigen. Scand. J. Immunol. 40:415-422, 1994.
  10. Bright, RK, Shearer, MH and Kennedy, RC. Examination of lymphokines induced in mice following immunization with recombinant simian virus 40 large tumor antigen. Cancer Immunol. Immunother. 40:206-211, 1995.
  11. Bright, RK, Shearer, MH and Kennedy, RC. Nucleic Acid vaccination against viral induced tumors.  Ann. NY. Acad. Sci. 772:241-251, 1995.
  12. Bright, RK, Beames, B, Shearer, MH and Kennedy, RC. Protection against a lethal tumor challenge with simian virus 40 transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen. Cancer Res. 56:1126-1130, 1996.
  13. Bright, RK, Vocke, CD, Solomon, D, Fetsch, P, Duray, PH, Emmert-Buck, MR, Rhim, JS, Linehan, WM, Rosenberg, SA, and Topalian, SL. Generation and Characterization of Long- Term Human Prostate Epithelial Cell Lines Derived from Localized Cancer Specimens. Cancer Res. 57: 995-1002, 1997.
  14. Bright, RK, Shearer, MH, Pass HI, and Kennedy, RC. Immunotherapy of SV40-Induced tumors in mice:  A model for vaccine development. Dev. Biol Stand 94:341, 1998.
  15. Ohta, Y, Shridhar, V, Kalemkerian, GP, Bright RK, Watanabe, Y and Pass, HI. Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma. Cancer 85:2570, 1999.
  16. Watts, AM, Shearer, MH, Pass, HI, Bright, RK and Kennedy, RC. Comparison of simian virus 40 large T antigen recombinant protein and DNA immunization in the induction of protective immunity from experimental pulmonary metastasis. Cancer Immunol Immunother 47:343, 1999.
  17. Virgin, JB, Hurley, PM, Cher, MP, Nahhas, F, Bebchuk, KG, Mohamed, AN, Sakr, WA, Bright, RK, and Cher, ML. Isochromosome 8q is associated with 8p loss of heterozygosity in a prostate cancer cell line. Prostate, 41:49-57, 1999.
  18. Ohta, Y, Shridhar, V, Bright, RK, Kalemkarian, G, Watanabe, and Pass, HI. VEGF and VEGF Type C Play an Important Role in Angiogenesis and Lymphangiogenesis in Human Malignant Mesothelioma. Br J Cancer 81:54-61, 1999.
  19. Housseau F, Bright RK, Nishimura M, and Topalian SL. A shared prostate cancer- associated antigen recognized by non-classical MHC restricted CD8+ T cells. J. Immunol. 163:6330-6337, 1999.
  20. Pauley, RJ, Santner, SJ, Bright, RK and Santen, RJ. Regulated CYP19 aramatase transcription in breast stromal fibroblasts. J. Clin. Endocrinology and Metabolism, 85:837- 846, 2000.
  21. Watts AM, Bright RK and Kennedy RC. DNA Cancer Vaccination Strategies Target SV40 Large Tumor Antigen in a Murine Experimental Metastasis Model. Dev. Biol. (Basel) 104:143-147, 2000.
  22. Watts AM, Shearer MH, Bright RK and Kennedy RC. Animal Models of SV40 Large Tumor Antigen Induced Tumors and Immunotherapy using Tumor Specific Antigen Based Strategies. Recent Res. Devel. Cancer.  2:257-270, 2000.
  23. Iordanov, M.S., J. Wong, D.L. Newton, S.M. Rybak, R.K. Bright, R.A. Flavell, R.J. Davis, and B.E. Magun. Differential requirement for the stress-activated protein kinase/c-Jun NH2- terminal kinase in RNA damage-induced apoptosis in primary and in immortalized fibroblasts. MCBRC 4:122-128, 2000.
  24. Dong Z, Nemeth JA, Cher ML, Palmer KC, Bright RK, Fridman R. Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression      in      co-cultures      of      prostate      cancer      and      stromal      cells. Int J Cancer. 93(4):507-15, 2001.
  25. Meijer SL, Dols A, Hu HM, Jensen S, Poehlein CH, Chu Y, Winter H, Yamada J, Moudgil T, Wood WJ, Doran T, Justice L, Fisher B, Wisner P, Wood J, Vetto JT, Mehrotra R, Rosenheim S, Weinberg AD, Bright RK, Walker E, Puri R, Smith JW 2nd, Urba WJ, Fox BA. Immunological and molecular analysis of the sentinel lymph node: a potential approach to predict outcome, tailor therapy, and optimize parameters for tumor vaccine development.
    • J. Clin. Pharmacol. ,2001.Jul;Suppl:81S-94S.
  26. Kawakami, K., Husain, SR, Bright, RK, and Puri, RK. Gene Transfer of Interleukin 13 Receptor a2 Chain Dramatically Enhances the Antitumor Effect of IL-13 Receptor-Targeted Cytotoxin in Human Prostate Cancer Xenografts. Cancer Gene Ther 8:861-868, 2001.
  27. Bright RK, Kimchi,ET, Shearer MH, Kennedy RC and Pass HI. SV40 Tag Specific Cytotoxic T Lymphocytes Generated from the Peripheral Blood of Malignant Pleural Mesothelioma Patients. Cancer Immunol Immunother 50:682-690, 2002.
  28. Bright RK.  Peptide-based Cancer Vaccines. Leukemia. 16:970, 2002.
  29. Iordanov MS, Choi RJ, Ryabinina OP, Dinh TH, Bright RK, Magun BE. The UV (ribotoxic) stress response of human keratinocytes involves the unexpected uncoupling of the Ras-extracellular signal-regulated kinase signaling cascade from the activated epidermal growth factor receptor.  Mol. Cell. Biol. 22:5380, 2002.
  30. Kennedy RC, Shearer MH, Watts AM and Bright RK. CD4+ Lymphocytes Play a Critical Role in Antibody Production and Tumor Immunity against Simian Virus 40 Large Tumor Antigen.  Cancer Res.   63:1040, 2003.
  31. Lewis JD, Reilly BD and Bright RK. Tumor Associated Antigens from Discovery to Immunity. Int. Rev Immunol, 22(2):81-112, 2003.
  32. Bright RK.  Guest editor’s comments.  Int. Rev. Immunol. 22(2):195-197, 2003.
  33. Chiriva-Internati M, Grizzi F, Franceschini B, Hermonat PL, Bright RK, Bumm K, Diogaurdi N and Kast WM. Is sperm protein 17 a useful target for immunotherapy? Blood 102:2308, 2003.
  34. Grizzi F, Chiriva-Internati M, Franceschini B, Bumm K, Colombo P, Ciccarelli M, Donetti E, Gagliano N, Hermonat PL, Bright RK, Gioia M, Dioguardi N and Kast WM. J Histochem Cytochem 52:549-554, 2004.
  35. Kennedy RC, Shearer MH, Lowe DB, Jumper CA, Chiriva-Internati M and Bright RK. Anti-idiotype responses avbrogate anti-CD4 induced tolerance to a tumor specific antigen and promote systemic tumor immunity. Cancer Immunol Immunother. 2004 May 19 [Epub ahead of print], 2004.
  36. Chiriva-Internati M, Grizzi F, Bright RK, Kast WM. Cancer immunotherapy: avoiding the road to perdition. J Transl Med. 2004 Jul 29 [Epub ahead of print]
  37. Lowe DB, Tarbox JA, Kang HS, Bright RK, Shearer MH and Kennedy RC. In vitro Simian Virus 40 large tumor antigen expression correlates with differential immune responses following DNA immunization. Virology 332:28-37, 2005.
  38. Lewis JD, Shearer MH, Kennedy RC and Bright RK. Surrogate tumor antigen vaccination drives determinant spreading the induction of systemic tumor immunity and the rejection of spontaneous lung metastases. Cancer Research, 65(7):2938-2946, 2005.
  39. Lowe DB, Shearer MH, Jumper CA, Bright RK and Kennedy RC. Fcγ receptors play a dominant role in protective tumor immunity against viral-encoded tumor specific antigen in a murine model of experimental pulmonary metastases. J Virol 81:1313-1318, 2007.
  40. Lewis JD, Payton LA, Whitford JG, Byrne JA, Smith DI, Yang L and Bright RK. Induction of Tumorigenesis and Metastasis by the Murine Orthologue of Tumor Protein D52. Mol Ca Res 5(2):133-144, 2007.
  41. Payton LA, Lewis JD, Byrne JA and Bright RK. Metastasis associated self tumor protein D52 induces tumor immunity following active vaccination. Cancer Immunol Immunother. 57:799-811, 2008, Epub 2007.epub.
  42. Shehata M, Bieche I, Boutros R, Weidenhofer H, Fanayan S, Spalding L, Zeps N, Byth K, Bright RK, Lidereau R and Byrne JA. Non-redundant functions for tumor protein D52-like proteins support specific targeting of TPD52. Clin Cancer Res 14(16):5050-60,  2008.
  43. Westfall LW, Shearer MH, Jumper CA, White GL, Papin JF, Eberle R, Butel JS, Bright RK, Kennedy RC. Evidence of Simian Virus 40 Exposure in a Colony of Captive Baboons. Virology 377(1):54-62, 2008.
  44. Lewis JD, Payton LA, De Riese W, Byrne JA and Bright RK. Memory and Cellular Immunity Induced by a DNA Vaccine Encoding Self Antigen TPD52 Administered with Soluble GM-CSF Cancer Immunol Immunother 58:1337-1349, 2009. (epub Jan 24, 2009).
  45. Lowe DB, Shearer MH, Jumper CA, Bright RK, Kennedy RC. Tumor immunity against an SV40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase. J. Virol. 84:883-893, 2010.
  46. Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Bright RK, Kennedy RC. CD4+ T Lymphocytes Are Critical Mediators of Tumor Immunity to Simian Virus 40 Large Tumor Antigen Induced by Vaccination with Plasmid DNA.J Virol. 14:7216-7224, 2011.
  47. Aldrich JF, Shearer MH, Lowe DB, Winn RE, Jumper CA, Kennedy, RC, Bright RK. The Role of Gamma Interferon in DNA Vaccine-Induced Tumor Immunity Targeting Simian Virus 40 Large Tumor Antigen Cancer Immunol Immunother 62:371-82, 2013.
  48. Wright J, Dungrawala H, Bright RK and Schneider BL. A growing role for hypertrophy in senescence. FEMS Yeast Research FEMS Yeast Res. 13:2-6, 2013.
  49. Bright JD, Schultz HN, Byrne JA and Bright RK. Injection Site and Regulatory T Cells Influence Durable Vaccine-Induced Tumor Immunity to an Over-Expressed Self Tumor Associated Antigen. OncoImmunology 7(2):(e25049) 1- 11, 2013.
  50. Bright JD, Aldrich JF, Byrne JA and Bright RK. Vaccination with the Prostate Cancer Over- Expressed Tumor Self-Protein TPD52 Elicits Protective Tumor Immunity and a Potentially Unique Subset of CD8+ T Cells Austin J Clin Immunol. 1(2), 2014. http://www.austinpublishinggroup.com/clinical-immunology/fulltext/ajci-v1-id1007.php
  51. Roslan N, Bièche I, Bright RK, Daly R, Lidereau R, Chen Y, Byrne JA. TPD52 represents a survival factor in ERBB2-amplified breast cancer cells. Molec Carcinogenesis. 53:807-19, 2014.
  52. Jennifer A. Byrne, Sarah Frost, Yuyan Chen, and Robert K. Bright. Cancer Biology: Tumor protein D52 (TPD52 ) and cancer: oncogene understudy, or understudied oncogene?Tumour Biol (epub) 2014.
  53. Bright RK, Bright JD and Byrne JA. Overexpressed Oncogenic Tumor-Self Antigens: New Vaccine Targets. Invited contribution, commissioned manuscript for: Human Vaccines and Immunotherapeutics, (epub) 2014.
  54. Kamili A, Roslan N, Frost S, Cantrill L, Wang D, Della-Franca A, Bright RK et al. TPD52 Expression Increases Neutral Lipid Storage within Cultured Cells (submitted).
  55. Bright JD, Byrne JA and Bright RK. Heterologous Prime-Boost Vaccination Targeting the Prostate Cancer Over-Expressed Tumor Self Protein (submitted).

Book Chapters And Reviews

  1. Mernaugh, RL, Bright, RK, and Kennedy, RC. Active immunization strategies using anti- idiotypic antibodies. In Vaccines: New Approaches to Immunologic Problems. (RL Ellis, Ed.).  Butterworth press, pp. 391-401, 1991.
  2. Bright, RK, and Pass, HI. Tumor Immunity and Vaccination against Viral Induced Tumors,.
    In:    Sourcebook    for    Asbestos    Related    Diseases,    Peters    and    Peters    ed. 1998.
  3. Watts, A. M., Kennedy, R.C., and Bright, R.K. 1999. Antibody-BasedMechanisms of Tumor Immunity.  In:  The Antibodies (J.D. Capra and M.Zanetti, eds.) Volume 6, Chapter 2, pp.31-62. Harwood Academic Publishers. New York, NY.
  4. Bright, RK. The Basis of Therapeutics: Immunology of Lung Cancer. In: Lung Cancer: Principles and Practice, Second Edition. Pass, Mitchell, Johnson, Turrisi and Minna eds. 2000.
  5. Pass HI, Kalemkerian G and Bright RK. Novel Molecular and Immunotherapeutic Strategies for Lung Cancer. Chest Surg. Clin. N. Am. 11:189-212, 2001.
  6. Bright, RK and Lewis JD. Long-term Culture of Normal and Malignant Human Prostate Epithelial Cells. In: Culture of Specialized Cells, Freshney Ed., Culture of Tumor Cells, Pfragner and Frehsney, Eds., 2003.
  7. Kennedy, R.C., Shearer, M.H., and Bright, R.K. DNA vaccines as cancer treatment modalities. In: DNA Vaccines. Ed. Ertl, H.C.J.. Eurekah.com and Kluwer Academic / Plenum Publishers.,pp. 195-213, 2003.
  8. Bright, RK and Jumper CA. Immunotherapy (Lung Cancer). In: Lung Cancer: Principles and Practice, Third Edition. Lippincott Williams and Wilkins. Pass, Carbone, Johnson, Minna and Turrisi, eds. Chapter 53, page 754, 2004.
  9. Bright, RK. Immunology. In: PreTest Self-Assessment and Review (USMLE), 14th Edition. McGraw Hill. Grisham M., ed. Chapter 8, page 383, 2013.
  10. Jennifer A. Byrne, Sarah Frost, Yuyan Chen, and Robert K. Bright. Cancer Biology: Tumor protein D52 (TPD52 ) and cancer: oncogene understudy, or understudied oncogene?Tumour Biol (epub) 2014.
  11. Bright RK, Bright JD and Byrne JA. Overexpressed Oncogenic Tumor-Self Antigens: New Vaccine Targets.
    Invited contribution, commissioned manuscript for:     Human Vaccines and Immunotherapeutics, (epub) 2014.

Editorships

  1. Bright, RK, Editor, Tumor Immunobiology and Cancer Vaccines. In: International Reviews of Immunology, 22(2), 2003.
  2. Bright, RK, Editor, Tumor Immunobiology and Cancer Vaccines. In: International Reviews of Immunology, 22(3-4), 2003.
  3. Text Book Content Reviewer:           Immunology IV Clinical Applications in Health and Disease, Bellanti, I Care Press, Inc., 2012.
  4. Associate Editor: ISRN Immunology (current)
  5. Editorial Board: Austin Journal of Clinical Immunology (current)

Published Abstracts: (Selected)

  • Bright, RK, Vocke, CD, Solomon, D, Fetsch, P, Duray, PH, Emmert-Buck, MR, Rhim, JS, Linehan, WM and Topalian, SL. Generation and Characterization of Long-Term Human Prostate Epithelial Cell Lines from Primary Cancer Specimens. Keystone Symposium on Molecular Mechanisms of Breast and Prostate Cancer, Taos, New Mexico, 1996.
  • Hurley, PM,Virgin, JB, Nanhas, F, Bright, RK, Mohamed, AN, Sakr, WA and Cher, MA. Isochromosome 8q in a Low Passage Cell Line from a Primary ProstateAdenocarcinoma.1997.
  • Jin-San Zhang, Matthew Nelson, Viji Shridhar, Robert K. Bright and David I Smith. High throughput screening for differentially expressed genes in matched normal/tumor prostate epithelial cell lines. 1998.
  • Housseau F, Bright RK, Nishimura M, and Topalian SL. A Shared prostate cancer-associated antigen recognized by non-classical MHC restricted CD8+ T cells. AACR, annual meeting Philadelphia, PA. 1999.
  • Dong Z, Bright RK, Palmer KC and Fridman R. Differential regulation of MMP-9 and TIMP-1 expression in co-cultures of primary prostate cancer cells and fibroblasts. AACR, annual meeting Philadelphia, PA. 1999.
  • Watts AM, Bright RK, and Kennedy RC. CD4+ T cells and Antibody are Required for Rejection of Tumors in a Murine Experimental Metastasis Model. FASEB, AAI, annual meeting, Seattle, WA. 2000.
  • Bright RK, Zang JS, Kimchi ET, Adams JW, Shridhar V and Smith DI. A Novel Prostate Tumor Associated Antigen Identified by Differential Gene Epxression Analysis. FASEB, AAI, annual meeting, Seattle, WA. 2000.
  • Yang L and Bright RK. Discovery of New Prostate Cancer Markers Using a Novel cDNA Mini- Array: Over-expression of Arsenic ATPase in Human Prostate Cancer. ACS, annual Presidents Meeting, Del Mar, CA, 2001.
  • Yang L, Urba WJ and Bright RK. Identification of a Novel Gene Over-expressed in Human Prostate Cancer Using Differential Gene Expression Analysis. AACR, annual meeting, San Francisco, CA, 2002.
  • Robert RK, Lewis JD, Shearer MH, Sweeney MM, and Kennedy RC. A Transgene Targeted Recombinant Vaccine Activates Cross Presentation of Unknown Cancer Associated Antigens and Induces Systemic Protective Tumor Immunity In a model for Metastatic Breast Cancer. Exp. Biol., FASEB, AAI annual meeting, New Orleans, LA., 2002.
  • Jennifer D. Lewis, Erin K. Patterson, Michael Shearer, Ronald C. Kennedy, and Robert K. Bright. Vaccine Strategies to Induce Tumor-Specific Immunity in the Absence of Known Tumor Associated Antigens.  AACR Annual Meeting, Washington, DC, 2003.
  • Erin K. Patterson, Jennifer D. Lewis, Jennifer A. Byrne, Michael H. Shearer, Ronald C. Kennedy and Robert K. Bright. The Tumor Associated Antigen TPD52: A Potential Target for the Immunologic Therapy of Breast, Prostate and Lung Cancer. AACR Annual Meeting, Washington, DC, 2003.
  • Jennifer D. Lewis and Robert K. Bright. Surrogate Tumor Antigen (STA) Surface Expression May Be Required For Cross-Priming and Induction of Systemic Tumor Immunity Following STA-Based Vaccination.  AACR Annual Meeting, Orlando, Fl. 2004.
  • Robert K. Bright, Laura A. Payton and Jennifer D. Lewis. Self Antigen TPD52 and TLR9 Ligand as a Protein-Based Cancer Vaccine. AACR Annual Meeting, Anaheim, CA. 2005.
  • Jennifer D. Lewis, Laura A. Payton and Robert K. Bright. Induction of Tumorigeneis and Metastasis by the Murine Homologue of Tumor Protein D52 (TPD52). AACR Annual Meeting, DC. 2006.
  • Laura A. Payton, Jennifer D. Lewis and Robert K. Bright. Self Protein Murine TPD52 (mD52) Induces Anti-Tumor Immunity Following Active Vaccination. AACR Annual Meeting, DC. 2006.
  • Mona Shehata, Rose Boutros, Robert K. Bright and Jennifer Byrne. In Vitro Models for Tumor Protein D52 Function in Cancer Cells. AACR Annual Meeting, Los Angeles, CA. 2007.
  • Robert K. Bright, Jennifer D. Lewis and Laura A. Payton. Memory and protective cellular immunity induced by the murine orthologue of metastasis associated protein TPD52. AAI annual meeting, Miami, FL 2007.
  • Adam R. Wolfe, Jennifer D. Lewis, Masoud Z Moghaddam, Satomi Niwayama, Jason Hurt, Samuel Prien, Jennifer A Byrne, and Robert K. Bright A 2-D proteomics approach to identifying Tumor Associated Antigens.  HHMI Research Day, TTU, Lubbock, TX 2008.
  • Lewis JD, Payton LA, De Riese W, Byrne JA and Bright RK. Memory and Cellular Immunity Induced by a DNA Vaccine Encoding Self Antigen TPD52 Administered with Soluble GM-CSF. Cancer Immunology and Immunotherapy: realizing the promise. NIH/NCI, Bethesda, MD 2008.
  • Adam R. Wolfe, Jennifer D. Lewis, Masoud Z. Moghaddam, Satomi Niwayama, Jennifer A. Byrne, Samuel Prien and Robert K. Bright. A 2-Dimensional Proteomics-Based Approach to Identify Tumor Associated Antigens, AACR Tumor Immunology Conference, Miami, FL, 2008.
  • Jennifer D. Bright, Heather N. Schultz and Robert K. Bright. Inhibition of Tumor Formation in Mice following Vaccination with DNA Encoding a Novel Xenogeneic Tumor Associated Auto- Antigen.  AACR Annual Meeting, Washington DC, 2010.
  • Della-Franca A, Catchpoole DR, Bright RK, deFazio A, and Byrne JA. Molecular mechanisms underlying cellular transformation by Tumor protein D52 overexpression. AACR Annual Meeting, Washington DC, 2010.
  • Jennifer D. Bright and Robert K. Bright. The Over-Expressed Self-Tumor Antigen TPD52 as a Cancer Vaccine Target. CDMRP, PCRP, IMPaCT 2011, Orlando, FL., 2011.
  • Roslan N, Bièche I, Bright RK, Lidereau R, Chen Y, and Byrne JA. TPD52 Represents a Survival Factor in ERBB2-Amplified Breast Cancer Cells. 1st International Conference on Molecular Diagnostics and Biomarker Discovery, Penang, Malaysia, October 2013.
  • Syapin PJ, Segura I, Al-Hasan Y, Scheible M, Basinger K, Bright RK, Grisham MB and Bergeson SE. Anit-Drinking Activity of Tetracycline Derivatives. Research Society on Alcoholism. 2014.
  • Peter J. Syapin, Patrick C. Marquardt, Clayton L. Allison, Yazan M. Al-Hasan, Carol Baby, Matthew Schieble, Katie L. Furr, Matthew B. Grisham, Robert K. Bright and Susan E. Bergeson. Sex Differences In Response To Drug Treatments To Reduce Alcohol Consumption. Gender-Specific Medicine & Women’s Health Symposium. TTUHSC, Lubbock,  TX 2014.

Invited Expert Lectures:

  1. Symposium on SV40 as a Possible Human Pathogen. NIH, FDA and CDC joint sponsored. "SV40 Induced Tumors in Mice: A Model for Vaccine Development." 1997.
  2. Dept. of Pathology, Wayne State University. "Generation and Characterization of Immortal Human Prostate Tumor Cell Lines: In vitro Models for the Immunotherapy of Prostate Cancer." 1997. (Invitation- Dr. Virgin).
  3. Dept. of Immunology and Microbiology, Wayne State University. "SV40 Induced Tumors in Mice: A Model for Vaccine Development." 1997. (Invitation- Dr. Leon).
  4. Immunology Department, Wyeth-Lederle Vaccines and Pediatrics, Rochester, NY. "Tumor Immunology and Immunotherapy: In vitro and In vivo models for vaccine development." 1997.
  5. Dept. of Urology, SPORE group, University of Michigan. "Generation and Characterization of Immortal Human Prostate Tumor Cell Lines: In vitro Models for the Immunotherapy of Prostate Cancer." 1998.  (Invitation- Drs. Ken Pienta and Martin Sanda).
  6. Prostate Cancer Program, Mayo Clinic, Rochester, Minn. "Generation and Characterization of Immortal Human Prostate Tumor Cell Lines: In vitro Models for the Immunotherapy of Prostate Cancer." June, 1998. (Invitation- Drs. Don Tindall and David Smith).
  7. Argonex, tumor vaccine development program, Charlottesville, VA. “Novel Prostate Tumor Cell Lines: Cell Characterization and Immunologic Studies”.June, 1998. (Invitation- Drs. Don Hunt and Victor Engelhard)
  8. UroCorp, Inc., Oklahoma City, OK. “Novel Prostate Tumor Cell Lines: Cell Characterization and Immunologic Studies”. July, 1998. (Invitation-Drs. Gerry Marley and Bob Veltri).
  9. Oregon Health Sciences University and the Earle Chiles Research Institute, Portland, OR. “Toward the Immunotherapy of Prostate Cancer: CTL generation and tumor antigen identification.” October 13, 1998.  (Invitation- Drs. Walter Urba and Bernie Fox).
  10. Good Samaritan Hospital Prostate Cancer Support Group, Portland, OR. Prostate Cancer Research and Clinical Trials: The Hope for Therapeutic Vaccination. July, 1999.
  11. Oregon Medical Laser Center, Providence St. Vincent Hospital, Portland Oregon. “Immunotherapy of Prostate Cancer: tumor antigen identification and T cell-mediated immunity.” October, 1999.  (Invitation- Dr. Kenton Gregory).
  12. Dept. of Microbiology and Immunology, Oklahoma University Health Sciences Center, Oklahoma City, OK. “Active Immunotherapy of Cancer: Tumor Antigen Identification and CTL immunity”   Nov., 1999.  (Invitation- Dr. Ronald C. Kennedy).
  13. Cell Genesys, Clinical Research Group, Foster City, CA. “In Vitro Approaches for Establishing Immortal Human tumor cells”. February 3, 2000. (Invitation- Dr. Kristen Hege).
  14. Prostate Cancer Support Group “Man to Man”, Providence Health Systems, Providence Milwaukie Hospital, Milwaukie, OR. “Prostate Cancer Research: The Process of Vaccine Development”.  February 17, 2000.
  15. Oregon Cancer Center Annual Retreat, 2000. “Human Prostate-Derived Tumor and Normal Cell Lines: In Vitro Models for Differential Gene Expression Analysis”. July 14, 2000, Skamania Lodge, Stevenson, Washington.
  16. NIH consortium on SV40 and human malignancies. Immune response to SV40 Tag and it’s use a vaccine for SV40 positive pleural mesotheliomas. January 16-17, 2001, Natcher building, NIH, Bethesda, MD.
  17. Dept. of Surgery, University of Chicago, Chicago, IL. “Human Prostate-Derived Tumor and Normal Cell Lines: In Vitro Models for the Study of Differential Gene Expression and T Cell-Mediated Tumor Immunity.” May 15, 2001. (Invitation- Dr. Michael I. Nishimura).
  18. Immunology Program, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL. “Human Prostate-Derived Tumor and Normal Cell Lines: In Vitro Models for the Study of Differential Gene Expression and T Cell-Mediated Tumor Immunity.” May 16, 2001. (Invitation- Dr. W. Martin Kast).
  19. Department of Microbiology and Immunology, Texas Tech. University Health Sciences Center, Lubbock, TX. “SV40 Tag Induced Tumor Immunity: Vaccine Studies in Mice and Men”. Sept. 2001. (Invitation- Dr. Ronald C. Kennedy).
  20. South West Cancer Center, Texas Tech University Health Sciences Center, Lubbock, TX. “Antigen Discovery and T Cell-Mediated Immunity in Human Prostate Cancer”. Sept. 2001. (Invitation – Dr. Everardo Cobos).
  21. Texas Regional Immunology Conference. The Woodlands, Texas. “Cytotoxic T Lymphocytes from a Prostate Cancer Patient Recognize a Shared Prostate Tumor Associated Antigen.” Nov. 2002.
  22. SWCC 3rd Ann. Res. Symposium. Lubbock, Texas. “Vaccine Strategies to Induce Tumor- Specific Immunity in the Absence of Known Tumor Associated Antigens.” Nov. 2003.
  23. 6th Walker’s Cay Colloquium on Cancer Vaccines and Immunotherapy, Walker’s Cay, Abaco, Bahamas. “Prostate Cancer Antigen Discover”. March, 2004. (Invitation – Dr. Martin Kast, Dr. Hyam Levitsky…Sabin Vaccine Institute).
  24. American Cancer Society, Man to Man, prostate cancer education and support group. Lubbock, Texas.  “Prostate Cancer Vaccination:  Treatment or Prevention?”  December, 2004.
  25. Cancer Vaccines, Deans Grand Rounds, School of Medicine, TTUHSC, 2006.
  26. American Cancer Society, Man to Man, prostate cancer education and support group. Lubbock, Texas.  “Prostate Cancer Vaccination: Treatment or Prevention?” February 19, 2007.
  27. Department of Urology, TTUHSC, Grand Rounds. “TPD52: a novel vaccine target for prostate cancer.” February 15, 2008 (Invitation- Dr. Werner DeRiese)
  28. Hollings Cancer Center, Medical University of South Carolina. “Mining Immunogens in Tumors: targeting self to kill cancer?” June 10, 2008 (Invitation- Dr. Michael Nishimura)
  29. Pfizer Cancer Vaccine Center, LaJolla, CA. “Mining Immunogens in Tumors: targeting self to kill cancer” January 15, 2009.
  30. Department of Cell Physiology and Molecular Biophysics, TTUHSC. “Advances in the Active Immunotherapy of Cancer”.  November 5, 2009.
  31. TTUHSC Cancer Center. “Immuno-modulation to Enhance Immunity to Tumor Associated Auto-Antigens”.  November 11, 2009.
  32. TTUHSC Dept. of Urology Grand Rounds. “Immuno-modulation to enhance immunity to over-expressed self-oncoantigens“…the TPD52 story, April 30, 2010.
  33. Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences. “Vaccines Targeting Over-Epxressed Oncoantigens: the TPD52 story”. September 13, 2010 (Invitation- Dr. Thomas Keiber-Emmons)
  34. American Cancer Society, Man to Man, prostate cancer education and support group. Lubbock, Texas.  “Prostate Cancer Vaccination” Spring 2011.
  35. American Cancer Society, Man to Man, prostate cancer education and support group. Lubbock, Texas.  “Prostate Cancer Vaccination” Fall 2013.

 

ROBERT K. BRIGHT

Professor

 

  • : (806) 743-4592
    Fax: (806) 743-2334
  • DEPARTMENTDepartment of Immunology and Molecular Microbiology
    Texas Tech University Health Sciences Center
  • COUNTRYUSA